5.91  -0.49 (-7.66%)		01-20 16:00
Open: 6.17 High: 6.18 Volume: 57,758		Pre. Close: 6.4 Low: 5.74 Market Cap: 215(M)

Short term
Mid term
Targets	6-month :	7.98	1-year :	9.28
Resists	First :	6.83	Second :	7.94
Pivot price	6.44
Supports	First :	5.03	Second :	4.18
MAs	MA(5) :	6.14	MA(20) :	6.42
	MA(100) :	4.98	MA(250) :	3.15
MACD	MACD :	0	Signal :	0.1
%K %D	K(14,3) :	24.8	D(3) :	21.7
RSI	RSI(14): 46.3
52-week	High :	16.34	Low :	0.89

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.
[ ARMP ] has closed above bottom band by 23.5%. Bollinger Bands are 7.1% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

If tomorrow:	Open lower	Open higher
High:	6.19 - 6.22	6.22 - 6.25
Low:	5.66 - 5.7	5.7 - 5.73
Close:	5.86 - 5.92	5.92 - 5.97

Armata Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology. The company's product candidates include AP-SA02 for the treatment of Staphylococcus aureus bacteremia; AP-PA02 for Pseudomonas aeruginosa; and AP-PA03 for the treatment of pneumonia. It has a partnership agreement with Merck & Co. for developing synthetic bacteriophage candidates to target undisclosed infectious disease agents. The company is headquartered in Marina del Rey, California.

Wed, 14 Jan 2026
Armata Pharmaceuticals (ARMP) Price Target Increased by 33.33% to 12.24 - Nasdaq

Tue, 13 Jan 2026
Antibiotic-resistant Staphylococcus aureus study moves to Armata Phase 3 - Stock Titan

Mon, 05 Jan 2026
Jones Trading Initiates Coverage on Armata Pharmaceuticals (ARMP - GuruFocus

Tue, 18 Nov 2025
Armata Pharmaceuticals Announces Key Opinion Leader Webinar on S. aureus Bacteremia and AP-SA02 Hosted by Jones Research on November 25th at 10:00am EST - PR Newswire

Wed, 12 Nov 2025
Armata Pharmaceuticals, Inc. (ARMP) Reports Q3 Loss, Misses Revenue Estimates - Yahoo Finance

Wed, 12 Nov 2025
Armata Pharmaceuticals Announces Third Quarter 2025 Results and Provides Corporate Update - PR Newswire

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Underperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Underperform
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Outperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Underperform

Exchange: AMEX
Sector: Healthcare
Industry: Biotechnology
Shares Out	0 (M)
Shares Float	0 (M)
Held by Insiders	0 (%)
Held by Institutions	0 (%)
Shares Short	0 (K)
Shares Short P.Month	0 (K)

EPS	0
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	0
Profit Margin	0 %
Operating Margin	0 %
Return on Assets (ttm)	0 %
Return on Equity (ttm)	0 %
Qtrly Rev. Growth	0 %
Gross Profit (p.s.)	0
Sales Per Share	0
EBITDA (p.s.)	0
Qtrly Earnings Growth	0 %
Operating Cash Flow	0 (M)
Levered Free Cash Flow	0 (M)

PE Ratio	0
PEG Ratio	0
Price to Book value	0
Price to Sales	0
Price to Cash Flow	0

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.